文献速递儿科与产科急症重症综合管理与镇静镇痛心脑血管急症

识别重症儿童神经功能损害风险的可互操作模型

Interoperable Models for Identifying Critically Ill Children at Risk of Neurologic Morbidity.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论在重症儿童中,采用24小时时间窗与48小时特征工程的极端梯度提升模型识别神经功能损害,外部验证F1 0.37、AUC 0.81、需警报数4,并与血清GFAP相关(rs=0.34;P=.007)。

这项预后研究利用2010年1月1日至2022年12月31日美国西宾夕法尼亚州一家大型独立儿童医院四級儿科重症监护病房收治的全部患儿数据,开发机器学习模型识别获得性神经功能损害,并用2018年1月1日至2023年12月31日华盛顿、怀俄明、阿拉斯加、蒙大拿和爱达荷5州转诊中心四级儿科重症监护病房的患儿数据做外部验证。开发队列纳入18568次就诊(中位年龄70个月[IQR 18-161],女性8325例[45%]),外部验证队列纳入2018至2021年6825次就诊(中位年龄96个月[IQR 18-171],女性3159例[46%])。可泛化的极端梯度提升模型采用24小时时间窗和48小时特征工程窗口,验证点F1评分0.37(95%CI 0.33-0.40)、受试者工作特征曲线下面积0.81(95%CI 0.78-0.83)、需警报数4;验证点重新校准后Brier评分0.04。血清脑损伤生物标志物胶质纤维酸性蛋白水平与模型输出显著相关(rs=0.34;P=.007)。作者认为,需要前瞻性评估并完善与生物标志物耦合的儿科重症风险模型。

要点

  • 可泛化极端梯度提升模型采用24小时时间窗和48小时特征工程窗口,外部验证F1评分0.37(95%CI 0.33-0.40)、AUC 0.81(95%CI 0.78-0.83)、需警报数4。
  • 模型在验证点重新校准后Brier评分0.04,提示预测概率校准良好。
  • 血清胶质纤维酸性蛋白水平与开发点模型预测显著相关(rs=0.34;P=.007),为模型提供生物分子佐证。
  • 开发队列18568次就诊(2010-2022年,中位年龄70个月[IQR 18-161],女性8325例[45%]),外部验证6825次就诊(2018-2021年,中位年龄96个月[IQR 18-171],女性3159例[46%])。
  • 作者认为,需要前瞻性评估并完善儿科重症中与生物标志物耦合的风险模型。

适用人群与场景

  • 开发点:2010年1月1日至2022年12月31日入住美国西宾夕法尼亚州一家大型独立儿童医院四级儿科重症监护病房的全部患儿,排除后纳入18568次就诊(中位年龄70个月[IQR 18-161],女性8325例[45%])。
  • 外部验证点:2018年1月1日至2023年12月31日入住华盛顿、怀俄明、阿拉斯加、蒙大拿和爱达荷5州转诊中心一家大型独立儿童医院四级儿科重症监护病房的患儿,2018至2021年共6825次就诊(中位年龄96个月[IQR 18-171],女性3159例[46%])。

诊断标准与关键阈值

  • 神经功能损害结局在开发点采用可计算的复合定义,在验证点采用神经重症监护会诊医嘱定义。

研究设计与关键结果

  • 研究为预后研究,开发点纳入18568次就诊、外部验证点纳入6825次就诊;可泛化极端梯度提升模型采用24小时时间窗和48小时特征工程窗口。
  • 外部验证点F1评分0.37(95%CI 0.33-0.40)、受试者工作特征曲线下面积0.81(95%CI 0.78-0.83)、需警报数4。
  • 验证点重新校准后Brier评分0.04。
  • 血清胶质纤维酸性蛋白水平与开发点模型输出显著相关(rs=0.34;P=.007),该相关性来自便利队列。

证据类型、等级与局限

  • 证据类型:预后研究(预测模型开发与外部验证)。
  • 局限:原文未报告局限性;作者在结论中提出需要前瞻性评估并完善儿科重症中与生物标志物耦合的风险模型。

对床旁实践的改变

  • 该模型可用于识别儿科重症监护病房中神经功能损害风险较高的患儿,外部验证需警报数为4,即每4次警报对应1例神经功能损害。
  • 模型预测与血清胶质纤维酸性蛋白水平相关(rs=0.34;P=.007),作者认为需要前瞻性评估并完善与生物标志物耦合的风险模型。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Decreasing mortality in the field of pediatric critical care medicine has shifted practicing clinicians' attention to preserving patients' neurodevelopmental potential as a main objective. Earlier identification of critically ill children at risk for incurring neurologic morbidity would facilitate heightened surveillance that could lead to timelier clinical detection, earlier interventions, and preserved neurodevelopmental trajectory.

OBJECTIVES: To develop machine-learning models for identifying acquired neurologic morbidity in hospitalized pediatric patients with critical illness and assess correlation with contemporary serum-based, brain injury-derived biomarkers.

DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used data from all children admitted to a quaternary pediatric intensive care unit in a large, freestanding children's hospital in Western Pennsylvania between January 1, 2010, and December 31, 2022. External model validation used data from children admitted between January 1, 2018, and December 31, 2023, to a quaternary pediatric intensive care unit in a large, freestanding children's hospital that serves as a referral center for the 5-state region of Washington, Wyoming, Alaska, Montana, and Idaho.

EXPOSURES: Critical illness.

MAIN OUTCOMES AND MEASURES: The outcome was neurologic morbidity, defined according to a computable, composite definition at the development site or an order for neurocritical care consultation at the validation site. Models were developed using varying time windows for temporal feature engineering and varying censored time horizons between the last feature and the identified neurologic morbidity. A generalizable model created at the development site was optimized and assessed at an external validation site. Correlation was assessed between development site model predictions and measurements of brain biomarkers from a convenience cohort.

RESULTS: After exclusions, there were 18 568 encounters from 2010 to 2022 in the development site generalizable model cohort (median age, 70 [IQR, 18-161] months; 8325 [45%] female). There were 6825 encounters from 2018 to 2021 at the external validation site (median age, 96 [IQR 18-171] months; 3159 [46%] female). A generalizable extreme gradient boosted model with a 24-hour time horizon and 48-hour feature engineering window demonstrated an F1 score of 0.37 (95% CI, 0.33-0.40), area under the receiver operating characteristics curve of 0.81 (95% CI, 0.78-0.83), and number needed to alert of 4 at the validation site. After recalibration at the validation site, the Brier score was 0.04. Serum levels of the brain injury biomarker glial fibrillary acidic protein significantly correlated with model output (rs = 0.34; P = .007).

CONCLUSIONS AND RELEVANCE: This prognostic study of prediction models for detecting neurologic morbidity in critically ill children demonstrated a well-performing ensemble of models with biomolecular corroboration. Prospective assessment and refinement of biomarker-coupled risk models in pediatric critical illness are warranted.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Horvat CM, Barda AJ, Perez Claudio E, et al. Interoperable Models for Identifying Critically Ill Children at Risk of Neurologic Morbidity. JAMA Netw Open. 2025. PMID: 39903466. doi:10.1001/jamanetworkopen.2024.57469

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。